184 related articles for article (PubMed ID: 37873509)
21. Safety and efficacy of tofacitinib in 97 alopecia areata patients.
Nasimi M; Abedini R; Ghandi N; Teymourpour A; Babaie H
J Cosmet Dermatol; 2024 May; ():. PubMed ID: 38736269
[TBL] [Abstract][Full Text] [Related]
22. A randomized placebo-controlled single-center pilot study of the safety and efficacy of apremilast in subjects with moderate-to-severe alopecia areata.
Mikhaylov D; Pavel A; Yao C; Kimmel G; Nia J; Hashim P; Vekaria AS; Taliercio M; Singer G; Karalekas R; Baum D; Mansouri Y; Lebwohl MG; Guttman-Yassky E
Arch Dermatol Res; 2019 Jan; 311(1):29-36. PubMed ID: 30417279
[TBL] [Abstract][Full Text] [Related]
23. Treatment of alopecia areata in pre-adolescent children with oral tofacitinib: A retrospective study.
Jerjen R; Meah N; Trindade de Carvalho L; Wall D; Eisman S; Sinclair R
Pediatr Dermatol; 2021 Jan; 38(1):103-108. PubMed ID: 33099833
[TBL] [Abstract][Full Text] [Related]
24. Experience with oral tofacitinib in two adolescents and seven adults with alopecia areata.
Akdogan N; Ersoy-Evans S; Doğan S; Atakan N
Dermatol Ther; 2019 Nov; 32(6):e13118. PubMed ID: 31621150
[TBL] [Abstract][Full Text] [Related]
25. A Retrospective Review of Anthralin in Petrolatum in the Treatment of Alopecia Areata in the Pediatric Population.
Zafrir Y; Tantuco K; Tangtatco AJA; Ho N
J Cutan Med Surg; 2023; 27(5):449-453. PubMed ID: 37559401
[TBL] [Abstract][Full Text] [Related]
26. Tofacitinib (Selective Janus Kinase Inhibitor 1 and 3): A Promising Therapy for the Treatment of Alopecia Areata: A Case Report of Six Patients.
Shivanna CB; Shenoy C; Priya RA
Int J Trichology; 2018; 10(3):103-107. PubMed ID: 30034188
[TBL] [Abstract][Full Text] [Related]
27. Fractional CO
Abd ElKawy FAE; Aly SHM; Ibrahim SMA
Dermatol Ther; 2022 Jul; 35(7):e15553. PubMed ID: 35509110
[TBL] [Abstract][Full Text] [Related]
28. Tofacitinib for the treatment of alopecia areata and variants in adolescents.
Craiglow BG; Liu LY; King BA
J Am Acad Dermatol; 2017 Jan; 76(1):29-32. PubMed ID: 27816292
[TBL] [Abstract][Full Text] [Related]
29. Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata.
Kennedy Crispin M; Ko JM; Craiglow BG; Li S; Shankar G; Urban JR; Chen JC; Cerise JE; Jabbari A; Winge MC; Marinkovich MP; Christiano AM; Oro AE; King BA
JCI Insight; 2016 Sep; 1(15):e89776. PubMed ID: 27699252
[TBL] [Abstract][Full Text] [Related]
30. Tofacitinib as a treatment of alopecia areata in adolescents.
Morales-Miranda AY; Bueno-Arias GM; Aguirre-Félix ÓG; Tovar-Franco R
Bol Med Hosp Infant Mex; 2019; 76(4):182-187. PubMed ID: 31303654
[TBL] [Abstract][Full Text] [Related]
31. Comparative Efficacy of Injection Triamcinolone Acetonide given Intralesionally and through Microneedling in
Arora A; Bhalla M; Thami GP
Int J Trichology; 2022; 14(5):156-161. PubMed ID: 36404886
[TBL] [Abstract][Full Text] [Related]
32. Retrospective Analysis of the Effect of Comorbid Atopic Dermatitis on the Treatment Response to Topical Immunotherapy in Pediatric Alopecia Areata Patients.
Gök AM; Aşkın Ö; Serdaroğlu S; Kutlubay Z
Dermatol Pract Concept; 2024 Jan; 14(1):. PubMed ID: 38364396
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata over 52 Weeks of Continuous Therapy in Two Phase III Trials (BRAVE-AA1 and BRAVE-AA2).
Kwon O; Senna MM; Sinclair R; Ito T; Dutronc Y; Lin CY; Yu G; Chiasserini C; McCollam J; Wu WS; King B
Am J Clin Dermatol; 2023 May; 24(3):443-451. PubMed ID: 36855020
[TBL] [Abstract][Full Text] [Related]
34. Oral Methotrexate Monotherapy for Severe Alopecia Areata: A Single Center Retrospective Case Series.
Kinoshita-Ise M; Sachdeva M; Martinez-Cabriales SA; Shear NH; Lansang P
J Cutan Med Surg; 2021 Sep; 25(5):490-497. PubMed ID: 33715460
[TBL] [Abstract][Full Text] [Related]
35. Alopecia Universalis in an Adolescent Successfully Treated with Upadacitinib-A Case Report and Review of the Literature on the Use of JAK Inhibitors in Pediatric Alopecia Areata.
Kołcz K; Żychowska M; Sawińska E; Reich A
Dermatol Ther (Heidelb); 2023 Mar; 13(3):843-856. PubMed ID: 36639612
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and safety of different JAK inhibitors in the treatment of alopecia areata: a network meta-analysis.
Wei D; Chen Y; Shen Y; Xie B; Song X
Front Immunol; 2023; 14():1152513. PubMed ID: 37138884
[TBL] [Abstract][Full Text] [Related]
37. Real-Life Effectiveness and Tolerance of Baricitinib for the Treatment of Severe Alopecia Areata with 1-Year Follow-Up Data.
De Greef A; Thirion R; Ghislain PD; Baeck M
Dermatol Ther (Heidelb); 2023 Nov; 13(11):2869-2877. PubMed ID: 37717224
[TBL] [Abstract][Full Text] [Related]
38. Alopecia areata and tofacitinib: a prospective multicenter study from a Saudi population.
AlMarzoug A; AlOrainy M; AlTawil L; AlHayaza G; AlAnazi R; AlIssa A; AlSheikh A; AlKhalifah A; AlHarithy R
Int J Dermatol; 2022 Jul; 61(7):886-894. PubMed ID: 34716573
[TBL] [Abstract][Full Text] [Related]
39. Benefit and risk profile of tofacitinib for the treatment of alopecia areata: a systemic review and meta-analysis.
Guo L; Feng S; Sun B; Jiang X; Liu Y
J Eur Acad Dermatol Venereol; 2020 Jan; 34(1):192-201. PubMed ID: 31494993
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of the level of serum Interleukins (IL-2, IL-4, IL-15 andIL-17) and its relationship with disease severity in patients with alopecia areata.
Aşkın Ö; Yücesoy SN; Coşkun E; Engin B; Serdaroğlu S
An Bras Dermatol; 2021; 96(5):551-557. PubMed ID: 34281739
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
